Managing glucose levels in children, particularly those not on insulin therapy, presents a distinct clinical challenge due to the variability in paediatric metabolism and lifestyle. The recent clearance by the US Food and Drug Administration (FDA) of an over-the-counter (OTC) continuous glucose monitor (CGM) for children aged 2 years and older who do not use insulin offers a new tool for monitoring in this population.
Historically, continuous glucose monitoring has primarily been indicated for individuals with diabetes, particularly those on insulin therapy, to optimise glycaemic control and prevent acute complications. The expansion of CGM access to paediatric populations not requiring insulin represents a shift in monitoring strategies. This includes children with prediabetes, those at risk of hypoglycaemia, or those with other conditions where glucose monitoring may provide valuable clinical insights.
The Device and Its Indication
The FDA has granted clearance for an over-the-counter continuous glucose monitor for use in individuals aged 2 years and older who do not use insulin. This device is intended to monitor glucose trends and patterns over time. Its primary functions include the detection of episodes of hypoglycaemia and hyperglycaemia, which can be critical for early intervention and management in paediatric patients. The device is designed to provide real-time glucose readings, offering a more comprehensive picture of glucose dynamics compared to intermittent finger-prick blood glucose testing.
The clearance specifies that the device is not intended to replace professional medical advice or to be used for the diagnosis or screening of diabetes. Instead, it serves as an adjunctive tool to support individuals and their caregivers in understanding glucose fluctuations. For children, this can be particularly beneficial in identifying patterns related to diet, physical activity, and other lifestyle factors that influence glucose levels. The availability of an OTC option removes the requirement for a prescription, potentially increasing accessibility for families and caregivers who may benefit from this technology.
The device operates by measuring glucose levels in interstitial fluid via a small sensor inserted under the skin. Data is transmitted wirelessly to a compatible smart device or reader, allowing for continuous display of glucose values and trend arrows. Alarms can be configured to alert users to high or low glucose levels, providing timely information that can guide immediate actions, such as adjusting food intake or activity. The system is designed for ease of use in a home setting, aligning with its OTC designation.
Clinical Context and Potential Impact
The clearance of an OTC CGM for non-insulin-using children aged 2 years and older addresses a previously unmet need in paediatric glucose management. While not a diagnostic tool, it offers a means for proactive monitoring. For children with conditions such as congenital hyperinsulinism, glycogen storage diseases, or those undergoing specific medical treatments that affect glucose metabolism, this device could provide valuable data to clinicians and caregivers. It may also be useful for children with obesity or a strong family history of type 2 diabetes, where early identification of dysglycaemia could inform preventative strategies.
The data collected by such devices can facilitate more informed discussions between families and healthcare providers regarding lifestyle modifications, nutritional guidance, and the timing of medical interventions. The ability to track glucose patterns without the need for frequent clinic visits or prescription renewals simplifies the monitoring process. However, it is imperative that caregivers understand the limitations of OTC devices and continue to engage with healthcare professionals for interpretation of data and clinical decision-making. The device's role is to provide information, not to dictate treatment protocols independently.
The FDA's clearance of an OTC continuous glucose monitor for non-insulin-using children aged 2 years and older marks a significant shift in paediatric glucose management. Clinicians should anticipate an increase in patient and caregiver inquiries regarding this technology. While not a diagnostic tool, its utility in providing real-time glucose trend data for conditions like prediabetes, risk of hypoglycaemia, or other metabolic concerns cannot be understated. The absence of a prescription barrier will undoubtedly broaden access, placing a greater onus on primary care physicians and paediatricians to interpret the data effectively and counsel families on its appropriate use and limitations.
For the industry, this move by the FDA signals a growing market for consumer-friendly medical devices beyond traditional disease management. Companies developing similar technologies will likely accelerate their efforts to capture this expanding demographic. The challenge will be to balance accessibility with clinical accuracy and to ensure that the data generated is actionable and does not lead to unnecessary anxiety or misinterpretation by non-medical users. The success of this OTC CGM will likely pave the way for further innovation in self-monitoring tools for various health parameters.
Patients and their families stand to benefit from enhanced awareness and proactive management of glucose fluctuations, particularly in scenarios where frequent clinic visits or invasive testing are impractical. However, it is critical that this convenience does not overshadow the need for professional medical guidance. The device provides data, but the clinical context and interpretation remain the domain of the healthcare provider. Education on when to seek medical advice based on CGM readings will be paramount to prevent self-diagnosis or inappropriate interventions, ensuring that this technological advancement truly serves to improve paediatric health outcomes.
- The Pivot An OTC CGM is now available for non-insulin-using children as young as 2 years old.
- The Data The device is indicated for monitoring glucose trends and patterns, and detecting episodes of hypoglycaemia and hyperglycaemia.
- The Action Clinicians should be aware of this new OTC option for paediatric patients who may benefit from glucose monitoring without a prescription.
ART-2026-382
Cite This Article
Team TLSFE. Fda clears otc cgm for non-insulin-using children aged 2+. The Life Science Feed. Updated June 14, 2026. Accessed June 14, 2026. https://thelifesciencefeed.com/endocrinology/diabetes-mellitus-type-1/news/fda-clears-otc-cgm-for-non-insulin-using-children-aged-2.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Medical Disclaimer
The information provided on The Life Science Feed is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider regarding any medical condition or treatment decision. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
